Document is current
Any future updates will be listed below
-
Authors
Bindra, Snehal
McGill, Marlon A.
Triplett, Marina K.
Tyagi, Anisha
Thaker, Premal H.
Dahmoush, Laila
Goodheart, Michael J.
Ogden, R. Todd
Owusu-Ansah, Edward
R Karan, Kalpita
Cole, Steve
Sood, Anil K.
Lutgendorf, Susan K.
Picard, Martin
-
Funding
Funding for this research was provided by:
American Cancer Society
National Cancer Institute (CA193249S1)
National Institutes of Health (GM119793)
Nathaniel Wharton Fund
- License Information
-
More Information
Article History
Received: 16 February 2021
Accepted: 4 May 2021
First Online: 2 June 2021
Competing interests
: Dr. Picard has consulted and received funding from Epirium Bio. Dr. Thaker has done consulting and/or speaking for Stryker, Iovance Biotherapeutics, Abbvie/Stemcentrx, Clovis Oncology, Unleash Immunolytics, Celsion, Merck, Aravive, Glaxo Smith Kline and Astra Zeneca, has research funding from Merck and Glaxo Smith Kline, and is a Celsion shareholder; Dr. Sood has done consulting for Merck, Astra Zeneca, and Kiyatec, has had research funding from M-Trap, and is a Biopath shareholder; other authors declare no potential conflict of interest.
